 B0571002 was terminated August 19 2008 due to the decision to discontinue development of PF-04603629 after observing in both B0571001 and B0571002 a trend for a reversible increase in heart rate within the normal range, which occurred at efficacious doses. Thus, the compound was primarily terminated due to safety concerns, although there was no immediate safety risk to any subject in the study. 